Advanced in Large-Cell Lung Carcinoma

Dr. Thierry M. Jahan

Oncology | Hematology
1600 Divisadero St, 
San Francisco, CA 
Advanced in Large-Cell Lung Carcinoma
1600 Divisadero St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thierry Jahan is an Oncologist and a Hematologist in San Francisco, California. Dr. Jahan is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Mesothelioma, Epithelioid Sarcoma, Adult Soft Tissue Sarcoma, and Lung Cancer.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1600 Divisadero St, San Francisco, CA 94115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy
A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy
Enrollment Status: Completed
Publish Date: December 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

43 Total Publications

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: October 22, 2020
Similar Doctors
Distinguished in Large-Cell Lung Carcinoma
Dr. Joel W. Neal
Oncology | Hematology Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Joel W. Neal
Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joel Neal is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Neal is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Distinguished in Large-Cell Lung Carcinoma
Dr. Matthew A. Gubens
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Matthew A. Gubens
Oncology

University Of California San Francisco

1600 Divisadero St, Mcb302, 
San Francisco, CA 
 (0.1 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Gubens is an Oncologist in San Francisco, California. Dr. Gubens is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Thymic Epithelial Tumor, and Lung Adenocarcinoma.

Distinguished in Large-Cell Lung Carcinoma
Dr. Michael L. Cheng
Oncology | Hematology
Distinguished in Large-Cell Lung Carcinoma
Dr. Michael L. Cheng
Oncology | Hematology

University Of California San Francisco

2330 Post St, 
San Francisco, CA 
 (0.1 miles away)
415-476-4029
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Cheng is an Oncologist and a Hematologist in San Francisco, California. Dr. Cheng is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and EGFR Positive Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jahan's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 19 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile